Your browser doesn't support javascript.
loading
Alphavirus antiviral drug development: scientific gap analysis and prospective research areas.
Reichert, Erin; Clase, Amanda; Bacetty, Ada; Larsen, Joseph.
Afiliação
  • Reichert E; Biological Therapeutics, Defense Threat Reduction Agency, Fort Belvoir, Virginia 22060-6201, USA.
Biosecur Bioterror ; 7(4): 413-27, 2009 Dec.
Article em En | MEDLINE | ID: mdl-20028250
The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Projetos de Pesquisa / Alphavirus Idioma: En Ano de publicação: 2009 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Projetos de Pesquisa / Alphavirus Idioma: En Ano de publicação: 2009 Tipo de documento: Article País de afiliação: Estados Unidos